Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
Vicky Makker
No relevant relationships to disclose
Virginia L. Filiaci
No relevant relationships to disclose
Lee-may Chen
No relevant relationships to disclose
Christopher Darus
No relevant relationships to disclose
James Erasmus Kendrick
No relevant relationships to disclose
Gregory Sutton
No relevant relationships to disclose
Katherine Moxley
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose